Targeting the DNA Damage Response Machinery for Lung Cancer Treatment

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Lung cancer remains a leading cause of global mortality, with current treatments offering limited efficacy for small-cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC).
• Advances in DNA sequencing enable systematic mutation discovery in tumors, paving the way for targeted therapies.
• Despite progress, the clinical application of DNA damage response (DDR) inhibitors in lung cancer is limited, with unexplored potential in combination strategies and biomarker-driven approaches.

Purpose of the Study:

• To review DNA repair pathways and their associated inhibitors.
• To discuss the current clinical status and future perspectives of DDR inhibitors in lung cancer treatment.
• To highlight the potential of biomarker-guided therapies for improving patient prognosis.

Main Methods:

• Literature review of DNA repair pathways and DDR inhibitors.
• Analysis of current clinical trial data for DDR inhibitors in SCLC and NSCLC.
• Discussion of emerging biomarkers and targeted treatment strategies.

Main Results:

• Several DNA repair pathways are implicated in lung cancer, with inhibitors targeting proteins like ATR, DNA-PK, and PARP showing therapeutic potential.
• Limited clinical trials have investigated DDR inhibitors for SCLC and NSCLC, indicating a need for further research.
• Biomarker discovery is crucial for identifying patient populations likely to benefit from targeted DDR inhibition.

Conclusions:

• DDR inhibitors represent a promising therapeutic avenue for lung cancer, particularly when used in combination or guided by specific biomarkers.
• Future clinical trials should focus on biomarker-enriched populations to optimize treatment strategies for SCLC and NSCLC.
• Further research into novel DDR inhibitor combinations and targeting multiple pathways is warranted to improve patient outcomes.